Dis-Chem Pharmacies Limited, together with its subsidiaries, engages in the retail and wholesale of healthcare products and pharmaceuticals in South Africa.
No risks detected for DCP from our risk checks.
Dis-Chem Pharmacies Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||R31.19|
|52 Week High||R17.20|
|52 Week Low||R32.60|
|1 Month Change||6.41%|
|3 Month Change||-2.53%|
|1 Year Change||81.23%|
|3 Year Change||11.04%|
|5 Year Change||n/a|
|Change since IPO||45.21%|
Recent News & Updates
|DCP||ZA Consumer Retailing||ZA Market|
Return vs Industry: DCP exceeded the ZA Consumer Retailing industry which returned 29.9% over the past year.
Return vs Market: DCP exceeded the ZA Market which returned 21.2% over the past year.
Stable Share Price: DCP is less volatile than 75% of ZA stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: DCP's weekly volatility (3%) has been stable over the past year.
About the Company
Dis-Chem Pharmacies Limited, together with its subsidiaries, engages in the retail and wholesale of healthcare products and pharmaceuticals in South Africa. It operates through two segments, Retail and Wholesale. It operates a chain of retail stores that offers a range of products, including dispensary, personal care and beauty, healthcare and nutrition, and baby care products, as well as other products, such as confectionary and household goods; and offers ancillary services that include clinics, and hair and beauty salons.
Dis-Chem Pharmacies Fundamentals Summary
|DCP fundamental statistics|
Is DCP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|DCP income statement (TTM)|
|Cost of Revenue||R20.44b|
Last Reported Earnings
Feb 28, 2021
Next Earnings Date
Nov 03, 2021
|Earnings per share (EPS)||0.78|
|Net Profit Margin||2.54%|
How did DCP perform over the long term?See historical performance and comparison
1.0%Current Dividend Yield
Is Dis-Chem Pharmacies undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: DCP (ZAR31.19) is trading below our estimate of fair value (ZAR36.57)
Significantly Below Fair Value: DCP is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: DCP is poor value based on its PE Ratio (40.1x) compared to the ZA Consumer Retailing industry average (28.7x).
PE vs Market: DCP is poor value based on its PE Ratio (40.1x) compared to the ZA market (11.4x).
Price to Earnings Growth Ratio
PEG Ratio: DCP is poor value based on its PEG Ratio (2x)
Price to Book Ratio
PB vs Industry: DCP is overvalued based on its PB Ratio (9.2x) compared to the ZA Consumer Retailing industry average (6.2x).
How is Dis-Chem Pharmacies forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DCP's forecast earnings growth (19.8% per year) is above the savings rate (8.8%).
Earnings vs Market: DCP's earnings (19.8% per year) are forecast to grow faster than the ZA market (12.5% per year).
High Growth Earnings: DCP's earnings are forecast to grow, but not significantly.
Revenue vs Market: DCP's revenue (10.4% per year) is forecast to grow faster than the ZA market (6.2% per year).
High Growth Revenue: DCP's revenue (10.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DCP's Return on Equity is forecast to be high in 3 years time (27.2%)
How has Dis-Chem Pharmacies performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DCP has high quality earnings.
Growing Profit Margin: DCP's current net profit margins (2.5%) are higher than last year (2.5%).
Past Earnings Growth Analysis
Earnings Trend: DCP's earnings have grown by 2.6% per year over the past 5 years.
Accelerating Growth: DCP's earnings growth over the past year (11.8%) exceeds its 5-year average (2.6% per year).
Earnings vs Industry: DCP earnings growth over the past year (11.8%) underperformed the Consumer Retailing industry 11.8%.
Return on Equity
High ROE: DCP's Return on Equity (23.3%) is considered high.
How is Dis-Chem Pharmacies's financial position?
Financial Position Analysis
Short Term Liabilities: DCP's short term assets (ZAR8.4B) exceed its short term liabilities (ZAR6.8B).
Long Term Liabilities: DCP's short term assets (ZAR8.4B) exceed its long term liabilities (ZAR3.4B).
Debt to Equity History and Analysis
Debt Level: DCP's debt to equity ratio (39.6%) is considered satisfactory.
Reducing Debt: DCP's debt to equity ratio has reduced from 187.9% to 39.6% over the past 5 years.
Debt Coverage: DCP's debt is well covered by operating cash flow (99.4%).
Interest Coverage: DCP's interest payments on its debt are well covered by EBIT (3.9x coverage).
What is Dis-Chem Pharmacies's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: DCP's dividend (1%) isn’t notable compared to the bottom 25% of dividend payers in the ZA market (3.05%).
High Dividend: DCP's dividend (1%) is low compared to the top 25% of dividend payers in the ZA market (8.04%).
Stability and Growth of Payments
Stable Dividend: DCP is not paying a notable dividend for the ZA market, therefore no need to check if payments are stable.
Growing Dividend: DCP is not paying a notable dividend for the ZA market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: DCP is not paying a notable dividend for the ZA market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DCP's dividend in 3 years as they are not forecast to pay a notable one for the ZA market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ivan Saltzman (71 yo)
Mr. Ivan Leon Saltzman has been the Chief Executive Officer and Executive Director of Dis-Chem Pharmacies Limited since May 25, 2005. Mr. Saltzman has 41 years of experience in the pharmaceutical sector in...
CEO Compensation Analysis
Compensation vs Market: Ivan's total compensation ($USD922.82K) is about average for companies of similar size in the ZA market ($USD921.12K).
Compensation vs Earnings: Ivan's compensation has been consistent with company performance over the past year.
Experienced Management: DCP's management team is seasoned and experienced (12.8 years average tenure).
Experienced Board: DCP's board of directors are considered experienced (7.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Dis-Chem Pharmacies Limited's employee growth, exchange listings and data sources
- Name: Dis-Chem Pharmacies Limited
- Ticker: DCP
- Exchange: JSE
- Founded: 1978
- Industry: Drug Retail
- Sector: Consumer Retailing
- Market Cap: R26.826b
- Shares outstanding: 860.08m
- Website: https://dischemgroup.com
Number of Employees
- Dis-Chem Pharmacies Limited
- 23 Stag Road
- Glen Austin
- South Africa
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/15 22:44|
|End of Day Share Price||2021/10/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.